VMD on XNAS, Health Care, Viemed Healthcare, Inc., job postings
Measures activity, not value. Not investment advice.
Revenue up 22% over 12 months to $310.4M and profit up 15%, and shares rose 34% in 12 months.
GoodLatest quarter revenue up 12% to $80.7M
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Viemed Healthcare Inc is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women's health products and services. The Company's primary service offerings focus on effective in-home treatment, with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. The company generates the majority of its revenue from medical equipment rental, sales, and supply.
Industry
Services-misc health & allied services, nec (Health Care)
expected around 3 Mar 2027 (an estimate: a year ago it reported on 4 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $80.7M, net income $4.6M.
31 Dec 2021RevenueNet incometallest bar $80.7M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$80.7M
$4.6M
30 Jun 2026
$78.1M
$2.8M
31 Mar 2026
$75.4M
$2.6M
31 Dec 2025
$76.2M
$5.6M
30 Sep 2025
$71.9M
$3.5M
30 Jun 2025
$63.1M
$3.2M
31 Mar 2025
$59.1M
$2.6M
31 Dec 2024
$60.7M
$4.3M
30 Sep 2024
$58.0M
$3.9M
30 Jun 2024
$55.0M
$1.5M
31 Mar 2024
$50.6M
$1.6M
31 Dec 2023
$50.7M
$3.5M
30 Sep 2023
$49.4M
$2.9M
30 Jun 2023
$43.3M
$2.3M
31 Mar 2023
$39.6M
$1.5M
31 Dec 2022
$37.5M
$2.4M
30 Sep 2022
$35.8M
$1.1M
30 Jun 2022
$33.3M
$967K
31 Mar 2022
$32.3M
$1.8M
31 Dec 2021
$32.0M
$4.1M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$310.4M
$254.8M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+22%
+3.8%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
$15.6M
$13.6M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
$0.38
$0.34
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
57.4%
57.9%
56.0%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
7.8%
8.3%
7.8%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
5.0%
5.3%
5.8%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
11.0%
-9.3%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
$21.4M
$5.4M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$9.7M
$11.1M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$5.0M
$21.1M
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$4.7M (net cash)
$10.0M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.03
0.06
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$3.96
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
20.7
24.7
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
1.0
1.1
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
1.0
1.2
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
2.2
4.1
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+12%
$80.7M vs $71.9M (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
+13%
$8.6M vs $7.6M (quarter ended 30 Sep 2026)
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+0.6%
165 13F filers vs 164
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
71%
26.7M shares held by 13F filers (30 Sep 2026) of 37.9M outstanding (27 Oct 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
4.0%
1.5M shares sold short (30 Oct 2026) of 37.9M outstanding (27 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
8.5
1.5M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-1.7%
1.5M shares sold short in the report before, 1.5M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
20%
20% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 42%
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$30K
4 quarters
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
0
0 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
–
0 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.
Unusual now sharp changes in the last 90 days, compared with its own past
Short interest 1.5M, 3.8× a year earlier
Price $8.52 on 20 Nov 2026, +34% over 12 months (12-month range $6.35 to $12.33)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders sold a net $1.6M in the last 12 months (the 12 months before: -$2.1M).Revenue per quarter. Revenue $80.7M in the latest quarter, +12% on a year earlier.Capital spending per quarter. Capital spending $8.6M in the latest quarter, +13% on a year earlier.Institutional holders (13F filers). 165 13F filers reported holding it in the latest 13F quarter, +32% on a year earlier.Lobbying spend. Lobbying spend: $30K published in the last 12 months (none in the 12 months before).
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.
Quarter ended 31 Dec 2021: $32.0M, +2.4% on a year earlier; public on 8 Mar 2022
Quarter ended 31 Mar 2022: $32.3M, +14% on a year earlier; public on 4 May 2022
Quarter ended 30 Jun 2022: $33.3M, +22% on a year earlier; public on 3 Aug 2022
Quarter ended 30 Sep 2022: $35.8M, +22% on a year earlier; public on 2 Nov 2022
Quarter ended 31 Dec 2022: $37.5M, +17% on a year earlier; public on 3 Mar 2023
Quarter ended 31 Mar 2023: $39.6M, +23% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $43.3M, +30% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $49.4M, +38% on a year earlier; public on 2 Nov 2023
Quarter ended 31 Dec 2023: $50.7M, +35% on a year earlier; public on 7 Mar 2024
Quarter ended 31 Mar 2024: $50.6M, +28% on a year earlier; public on 7 May 2024
Quarter ended 30 Jun 2024: $55.0M, +27% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $58.0M, +17% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $60.7M, +20% on a year earlier; public on 11 Mar 2025
Quarter ended 31 Mar 2025: $59.1M, +17% on a year earlier; public on 8 May 2025
Quarter ended 30 Jun 2025: $63.1M, +15% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $71.9M, +24% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $76.2M, +26% on a year earlier; public on 5 Mar 2026
Quarter ended 31 Mar 2026: $75.4M, +28% on a year earlier; public on 6 May 2026
Quarter ended 30 Jun 2026: $78.1M, +24% on a year earlier; public on 4 Aug 2026
Quarter ended 30 Sep 2026: $80.7M, +12% on a year earlier; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $6.7M, +38% on a year earlier; public on 8 Mar 2022
Quarter ended 31 Mar 2022: $4.0M, +121% on a year earlier; public on 4 May 2022
Quarter ended 30 Jun 2022: $7.0M, +116% on a year earlier; public on 3 Aug 2022
Quarter ended 30 Sep 2022: $6.3M, -21% on a year earlier; public on 2 Nov 2022
Quarter ended 31 Dec 2022: $5.6M, -16% on a year earlier; public on 3 Mar 2023
Quarter ended 31 Mar 2023: $4.7M, +18% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $6.1M, -13% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $7.4M, +17% on a year earlier; public on 2 Nov 2023
Quarter ended 31 Dec 2023: $7.9M, +42% on a year earlier; public on 7 Mar 2024
Quarter ended 31 Mar 2024: $6.0M, +28% on a year earlier; public on 7 May 2024
Quarter ended 30 Jun 2024: $8.9M, +47% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $11.0M, +49% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $11.8M, +49% on a year earlier; public on 11 Mar 2025
Quarter ended 31 Mar 2025: $15.5M, +158% on a year earlier; public on 8 May 2025
Quarter ended 30 Jun 2025: $8.1M, -9.0% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $7.6M, -31% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $8.7M, -26% on a year earlier; public on 5 Mar 2026
Quarter ended 31 Mar 2026: $6.7M, -57% on a year earlier; public on 6 May 2026
Quarter ended 30 Jun 2026: $8.5M, +4.1% on a year earlier; public on 4 Aug 2026
Quarter ended 30 Sep 2026: $8.6M, +13% on a year earlier; public on 5 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 79; public on 14 Feb 2022
31 Mar 2022 report: 82; public on 16 May 2022
30 Jun 2022 report: 70; public on 15 Aug 2022
30 Sep 2022 report: 62; public on 14 Nov 2022
31 Dec 2022 report: 75; public on 14 Feb 2023
31 Mar 2023 report: 80; public on 15 May 2023
30 Jun 2023 report: 96; public on 14 Aug 2023
30 Sep 2023 report: 106; public on 14 Nov 2023
31 Dec 2023 report: 97; public on 14 Feb 2024
31 Mar 2024 report: 108; public on 15 May 2024
30 Jun 2024 report: 114; public on 14 Aug 2024
30 Sep 2024 report: 118; public on 14 Nov 2024
31 Dec 2024 report: 139; public on 14 Feb 2025
31 Mar 2025 report: 136; public on 15 May 2025
30 Jun 2025 report: 121; public on 14 Aug 2025
30 Sep 2025 report: 125; public on 14 Nov 2025
31 Dec 2025 report: 126; public on 17 Feb 2026
31 Mar 2026 report: 145; public on 15 May 2026
30 Jun 2026 report: 164; public on 14 Aug 2026
30 Sep 2026 report: 165; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $10K published
Quarter from 1 Oct 2026: $30K published
What is unusual now
Made public in the last 90 days: it had 1.5M shares sold short in the 30 Oct 2026 report, 3.8× the same report last year; it also had 1.5M shares sold short in the 15 Oct 2026 report, 4.0× the same report last year. 6 sharp changes in all.
Short interest spike: had 1.5M shares sold short in the 30 Oct 2026 report, 3.8× the same report last year Public on 11 Nov 2026.
Reported lobbying spend: $30K in Q3 2026, $10K in Q4 2021. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Two or more unrelated kinds of records unusual within 30 days
1 Sep 2020confirmed
Confirmed across sources Filings + Financials and Short interest and volume
Viemed Healthcare(VMD): reported revenue of $42.9M for the quarter ended 30 Jun 2020, 1.9× the same quarter last year, while it had 1.1M shares sold short in the 14 Aug 2020 report, 22× the same report last year. Two unrelated kinds of activity within 35 days.
Financials: Quarterly revenue change, became public on 11 Aug 2020
Short interest and volume: Short interest spike, became public on 26 Aug 2020
Short interest and volume: Short interest spike, became public on 11 Sep 2020
The quarter ended 30 Jun 2020 against the 8 quarters before it.
this quarterearliernormal: $19.9MSee the evidence (3 changes)
Financials: Quarterly revenue change became public on 11 Aug 2020
Viemed Healthcare reported revenue of $42.9M for the quarter ended 30 Jun 2020, 1.9× the same quarter last year.
This period
$42.9M (the quarter ended 30 Jun 2020)
Normal quarter (median of 8 earlier)
$19.9M
Typical spread (median absolute deviation)
$2.7M
How far from its usual level
+5.7
Same quarter last year
$22.5M
History used
822 days
the quarter ended 30 Jun 20208 earlier quartersnormal: $19.9M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Short interest and volume: Short interest spike became public on 26 Aug 2020
Viemed Healthcare had 1.1M shares sold short in the 14 Aug 2020 report, 22× the same report last year.
This period
1.1M (the 14 Aug 2020 report)
Normal report (median of 24 earlier)
133K
Typical spread (median absolute deviation)
107K
How far from its usual level
+6.1
Same report last year
50K
History used
365 days
the 14 Aug 2020 report24 earlier reportsnormal: 133K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Sep 2020
Viemed Healthcare had 933K shares sold short in the 31 Aug 2020 report, 49× the same report last year.
This period
933K (the 31 Aug 2020 report)
Normal report (median of 24 earlier)
146K
Typical spread (median absolute deviation)
124K
How far from its usual level
+4.3
Same report last year
19K
History used
382 days
the 31 Aug 2020 report24 earlier reportsnormal: 146K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
11 Nov 2026Short interest and volume change
had 1.5M shares sold short in the 30 Oct 2026 report, 3.8× the same report last year.
Same report last year: 394K; its normal report is 428K.
See the evidence
This period
1.5M (the 30 Oct 2026 report)
Normal report (median of 24 earlier)
428K
Typical spread (median absolute deviation)
74K
How far from its usual level
+9.9
Same report last year
394K
History used
2,633 days
the 30 Oct 2026 report24 earlier reportsnormal: 428K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.5M shares sold short in the 15 Oct 2026 report, 4.0× the same report last year.
Same report last year: 384K; its normal report is 407K.
See the evidence
This period
1.5M (the 15 Oct 2026 report)
Normal report (median of 24 earlier)
407K
Typical spread (median absolute deviation)
54K
How far from its usual level
+14.0
Same report last year
384K
History used
2,618 days
the 15 Oct 2026 report24 earlier reportsnormal: 407K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.6M shares sold short in the 30 Sep 2026 report, 3.9× the same report last year.
Same report last year: 403K; its normal report is 404K.
See the evidence
This period
1.6M (the 30 Sep 2026 report)
Normal report (median of 24 earlier)
404K
Typical spread (median absolute deviation)
48K
How far from its usual level
+16.4
Same report last year
403K
History used
2,603 days
the 30 Sep 2026 report24 earlier reportsnormal: 404K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.3M shares sold short in the 15 Sep 2026 report, 2.9× the same report last year.
Same report last year: 461K; its normal report is 404K.
See the evidence
This period
1.3M (the 15 Sep 2026 report)
Normal report (median of 24 earlier)
404K
Typical spread (median absolute deviation)
48K
How far from its usual level
+12.9
Same report last year
461K
History used
2,588 days
the 15 Sep 2026 report24 earlier reportsnormal: 404K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.2M shares sold short in the 31 Aug 2026 report, 2.9× the same report last year.
Same report last year: 419K; its normal report is 404K.
See the evidence
This period
1.2M (the 31 Aug 2026 report)
Normal report (median of 24 earlier)
404K
Typical spread (median absolute deviation)
46K
How far from its usual level
+11.8
Same report last year
419K
History used
2,573 days
the 31 Aug 2026 report24 earlier reportsnormal: 404K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 787K shares sold short in the 14 Aug 2026 report, 1.9× the same report last year.
Same report last year: 423K; its normal report is 404K.
See the evidence
This period
787K (the 14 Aug 2026 report)
Normal report (median of 24 earlier)
404K
Typical spread (median absolute deviation)
44K
How far from its usual level
+5.9
Same report last year
423K
History used
2,556 days
the 14 Aug 2026 report24 earlier reportsnormal: 404K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 672K shares sold short in the 31 Jul 2026 report, 1.4× the same report last year.
Same report last year: 476K; its normal report is 404K.
See the evidence
This period
672K (the 31 Jul 2026 report)
Normal report (median of 24 earlier)
404K
Typical spread (median absolute deviation)
44K
How far from its usual level
+4.1
Same report last year
476K
History used
2,542 days
the 31 Jul 2026 report24 earlier reportsnormal: 404K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
spent $15.5M on capital projects in the quarter ended 31 Mar 2025, 2.6× the same quarter last year.
Same quarter last year: $6.0M; its normal quarter is $7.7M.
See the evidence
This period
$15.5M (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
$7.7M
Typical spread (median absolute deviation)
$1.6M
How far from its usual level
+3.2
Same quarter last year
$6.0M
History used
2,374 days
the quarter ended 31 Mar 20258 earlier quartersnormal: $7.7M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
reported revenue of $49.4M for the quarter ended 30 Sep 2023, 1.4× the same quarter last year.
Same quarter last year: $35.8M; its normal quarter is $34.5M.
See the evidence
This period
$49.4M (the quarter ended 30 Sep 2023)
Normal quarter (median of 8 earlier)
$34.5M
Typical spread (median absolute deviation)
$2.8M
How far from its usual level
+3.6
Same quarter last year
$35.8M
History used
2,009 days
the quarter ended 30 Sep 20238 earlier quartersnormal: $34.5M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
had 512K shares sold short in the 31 Aug 2023 report, 3.7× the same report last year.
Same report last year: 140K; its normal report is 137K.
See the evidence
This period
512K (the 31 Aug 2023 report)
Normal report (median of 24 earlier)
137K
Typical spread (median absolute deviation)
26K
How far from its usual level
+7.5
Same report last year
140K
History used
1,477 days
the 31 Aug 2023 report24 earlier reportsnormal: 137K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 539K shares sold short in the 15 Aug 2023 report, 3.1× the same report last year.
Same report last year: 172K; its normal report is 137K.
See the evidence
This period
539K (the 15 Aug 2023 report)
Normal report (median of 24 earlier)
137K
Typical spread (median absolute deviation)
26K
How far from its usual level
+8.0
Same report last year
172K
History used
1,461 days
the 15 Aug 2023 report24 earlier reportsnormal: 137K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 581K shares sold short in the 31 Jul 2023 report, 3.4× the same report last year.
Same report last year: 173K; its normal report is 137K.
See the evidence
This period
581K (the 31 Jul 2023 report)
Normal report (median of 24 earlier)
137K
Typical spread (median absolute deviation)
26K
How far from its usual level
+8.9
Same report last year
173K
History used
1,446 days
the 31 Jul 2023 report24 earlier reportsnormal: 137K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 629K shares sold short in the 14 Jul 2023 report, 2.5× the same report last year.
Same report last year: 252K; its normal report is 137K.
See the evidence
This period
629K (the 14 Jul 2023 report)
Normal report (median of 24 earlier)
137K
Typical spread (median absolute deviation)
26K
How far from its usual level
+9.9
Same report last year
252K
History used
1,429 days
the 14 Jul 2023 report24 earlier reportsnormal: 137K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 589K shares sold short in the 30 Jun 2023 report, 1.5× the same report last year.
Same report last year: 390K; its normal report is 137K.
See the evidence
This period
589K (the 30 Jun 2023 report)
Normal report (median of 24 earlier)
137K
Typical spread (median absolute deviation)
26K
How far from its usual level
+9.0
Same report last year
390K
History used
1,415 days
the 30 Jun 2023 report24 earlier reportsnormal: 137K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
spent $8.0M on capital projects in the quarter ended 30 Sep 2021, 3.2× the same quarter last year.
Same quarter last year: $2.5M; its normal quarter is $2.8M.
See the evidence
This period
$8.0M (the quarter ended 30 Sep 2021)
Normal quarter (median of 8 earlier)
$2.8M
Typical spread (median absolute deviation)
$726K
How far from its usual level
+4.8
Same quarter last year
$2.5M
History used
1,096 days
the quarter ended 30 Sep 20218 earlier quartersnormal: $2.8M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
had 1.8M shares sold short in the 15 Jun 2021 report, 3.4× the same report last year.
Same report last year: 531K; its normal report is 1.3M.
See the evidence
This period
1.8M (the 15 Jun 2021 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
92K
How far from its usual level
+3.5
Same report last year
531K
History used
670 days
the 15 Jun 2021 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported $110K of lobbying spend for the quarter ended 31 Dec 2020, 4.4× its normal quarter.
See the evidence
This period
$110K (the quarter ended 31 Dec 2020)
Normal quarter (median of 6 earlier)
$25K
Typical spread (median absolute deviation)
$5K
How far from its usual level
+4.2
History used
1,827 days
the quarter ended 31 Dec 20206 earlier quartersnormal: $25K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.
had 933K shares sold short in the 31 Aug 2020 report, 49× the same report last year.
Same report last year: 19K; its normal report is 146K.
See the evidence
This period
933K (the 31 Aug 2020 report)
Normal report (median of 24 earlier)
146K
Typical spread (median absolute deviation)
124K
How far from its usual level
+4.3
Same report last year
19K
History used
382 days
the 31 Aug 2020 report24 earlier reportsnormal: 146K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported revenue of $42.9M for the quarter ended 30 Jun 2020, 1.9× the same quarter last year, while it had 1.1M shares sold short in the 14 Aug 2020 report, 22× the same report last year. Two unrelated kinds of activity within 35 days.
See the evidence (3 changes)
Financials: Quarterly revenue change became public on 11 Aug 2020
Viemed Healthcare reported revenue of $42.9M for the quarter ended 30 Jun 2020, 1.9× the same quarter last year.
This period
$42.9M (the quarter ended 30 Jun 2020)
Normal quarter (median of 8 earlier)
$19.9M
Typical spread (median absolute deviation)
$2.7M
How far from its usual level
+5.7
Same quarter last year
$22.5M
History used
822 days
the quarter ended 30 Jun 20208 earlier quartersnormal: $19.9M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Short interest and volume: Short interest spike became public on 26 Aug 2020
Viemed Healthcare had 1.1M shares sold short in the 14 Aug 2020 report, 22× the same report last year.
This period
1.1M (the 14 Aug 2020 report)
Normal report (median of 24 earlier)
133K
Typical spread (median absolute deviation)
107K
How far from its usual level
+6.1
Same report last year
50K
History used
365 days
the 14 Aug 2020 report24 earlier reportsnormal: 133K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Sep 2020
Viemed Healthcare had 933K shares sold short in the 31 Aug 2020 report, 49× the same report last year.
This period
933K (the 31 Aug 2020 report)
Normal report (median of 24 earlier)
146K
Typical spread (median absolute deviation)
124K
How far from its usual level
+4.3
Same report last year
19K
History used
382 days
the 31 Aug 2020 report24 earlier reportsnormal: 146K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
26 Aug 2020Short interest and volume change
had 1.1M shares sold short in the 14 Aug 2020 report, 22× the same report last year.
Same report last year: 50K; its normal report is 133K.
See the evidence
This period
1.1M (the 14 Aug 2020 report)
Normal report (median of 24 earlier)
133K
Typical spread (median absolute deviation)
107K
How far from its usual level
+6.1
Same report last year
50K
History used
365 days
the 14 Aug 2020 report24 earlier reportsnormal: 133K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported revenue of $42.9M for the quarter ended 30 Jun 2020, 1.9× the same quarter last year.
Same quarter last year: $22.5M; its normal quarter is $19.9M.
See the evidence
This period
$42.9M (the quarter ended 30 Jun 2020)
Normal quarter (median of 8 earlier)
$19.9M
Typical spread (median absolute deviation)
$2.7M
How far from its usual level
+5.7
Same quarter last year
$22.5M
History used
822 days
the quarter ended 30 Jun 20208 earlier quartersnormal: $19.9M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Showing the newest 40 of 46 entries; narrow the window or the kind of data to see older ones.
Not listed: 89 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001729149
Ticker
VMD
Domain
viemed.com
Hq location
LA|LAFAYETTE|70508 (1 unverified)
Lobbying client
picard group obo viemed, sleep management llc d b a viemed, viemed, viemed healthcare
Name
East Alabama HomeMed, LLC, Home Medical Products, Inc, Home Sleep Delivered, L.L.C, Lehan Drugs, Inc and 9 more
Federal lobbying disclosures (LDA)7 records, 73 data points19 Nov 2015 to 30 Sep 2026
SEC Form 13F institutional holdings293 data points31 Mar 2018 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)84 records31 Jan 2018 to 4 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)653 data points31 Dec 2017 to 27 Oct 2026
SEC Form 4 insider transactions17 records, 56 data points23 Dec 2022 to 26 Jun 2026
FINRA short interest (twice monthly)519 data points15 Aug 2019 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)3658 data points9 Aug 2019 to 20 Nov 2026